[V4Q5]dDAVP

[V4Q5]dDAVP is a second-generation synthetic peptide analog of arginine vasopressin (AVP) and a selective agonist of the arginine vasopressin type 2 receptor (AVPR2). Developed primarily by researchers at the National University of Quilmes in Argentina, it is a modified version of desmopressin (dDAVP) featuring substitutions of valine at position 4 and glutamine at position 5. These modifications enhance its antitumor and antimetastatic properties compared to the parent compound. Preclinical studies have demonstrated that [V4Q5]dDAVP possesses significant antiproliferative, antimetastatic, and anti-angiogenic activities across various cancer types, including small-cell lung cancer (SCLC), breast cancer, and colorectal cancer. Its mechanism of action involves the activation of V2R expressed on tumor cells and the tumor microvasculature, leading to cytostatic effects and inhibition of metastatic spread.

Other names

1-deamino-4-valine-5-glutamine-8-D-arginine vasopressin[V4Q5]desmopressin